



## Rallybio to Present at Upcoming Investor Conferences

August 27, 2024 at 8:00 AM EDT

NEW HAVEN, Conn.--(BUSINESS WIRE)--Aug. 27, 2024-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in the following upcoming investor conferences:

- **2024 Wells Fargo Healthcare Conference** in Everett, MA on Thursday, September 5, 2024. Stephen Uden, M.D., Chief Executive Officer, will participate in a fireside chat at 3:45 p.m. ET.
- **H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference** in New York, NY on Tuesday, September 10, 2024. Dr. Uden will present a corporate overview at 11:00 a.m. ET.

Live webcasts of the Wells Fargo fireside chat and H.C. Wainwright presentation will be accessible through the [Events and Presentations](#) section of Rallybio's website at [www.rallybio.com](http://www.rallybio.com). A replay of the webcasts will be available for 30 days following each presentation.

### About Rallybio

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit [www.rallybio.com](http://www.rallybio.com) and follow us on [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20240826376744/en/>

### Investors

Samantha Tracy  
Rallybio Corporation  
(475) 47-RALLY (Ext. 282)  
[investors@rallybio.com](mailto:investors@rallybio.com)

Kevin Lui  
Precision AQ  
(212) 698-8691  
[Kevin.Lui@precisionaq.com](mailto:Kevin.Lui@precisionaq.com)

### Media

Victoria Reynolds  
Mission North  
(760) 579-2134  
[rallybio@missionnorth.com](mailto:rallybio@missionnorth.com)

Source: Rallybio Corporation